Exploring Catalysis in API Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Exploring Catalysis in API Synthesis
Chemocatalysis and biocatalysis are important elements of an effective strategy for improving yield and stereoselectivty.


Pharmaceutical Technology
Volume 34, Issue 5, pp. 42-46

Heterogeneous catalysis


Formulation development forum: in vivo imaging emerges as a tool in preclinical and clinical development
Better understanding of the molecular science of heterogeneous catalysts is an important part of research efforts in catalysis. Heterogeneous catalysts, which are in a different phase from that of the reactants, offer certain advantages compared with homogeneous catalysts, which are in the same phase as the reactants. Typically solids, heterogeneous catalysts can be more easily separated and recovered in a product stream and therefore lend themselves to continuous chemical processing. They are also generally more tolerant of extreme operating conditions than homogeneous catalysts (5).

A challenge in heterogeneous catalysis, however, is that the materials used as heterogeneous catalysts can contain a distribution of particles and pores of different sizes. To better understand the function of the active site of a heterogeneous catalyst, three key elements need to be considered, according to a recent report by the Dutch National Research School Combination Catalysis Controlled by Chemical Design (NRSC-Catalysis). NRSC-Catalysis represents scientists from various disciplines from nine Dutch universities: the University of Amsterdam (UvA), University Amsterdam (VA), Delft University of Technology, Eindhoven University of Technology, University of Nijmegen, University of Groningen, Leiden University, Utrecht University, and the University of Twente. NRSC-Catalysis issued the report to highlight the advances in catalyst design and development made by the group and to offer a perspective on future research efforts (5).

Three elements that need to be considered in heterogeneous catalyst development are: the chemical nature of the active center (0.1-nm length scale) that controls the bond-breaking and bond-making action of the catalyst; the local environment such as its hydrophilic or hydrophobic nature and the stereochemistry that is affected by processes on nanometer-length scales; and the accessibility of active centers that affect local concentrations and the rate of transport of molecules (5).

Researchers at the University of California at Berkeley recently reported on a method for applying heterogeneous catalysts to known homogeneous catalytic reactions through the design and synthesis of electrophilic platinum nanoparticles (6). These nanoparticles were selectively oxidized by a hypervalent iodine species. They catalyzed a range of p-bond activation reactions previously only catalyzed through homogeneous processes (6). The importance of this method is that it shows the potential of using nanoparticles to develop novel catalytic reactions that were previously not accessible through heterogeneous catalysis (6, 7). The researchers also reported that the platinum polyamidoamine dendrimer-capped nanoparticles showed better activity and recyclability compared with larger, polymer-capped analogs (6, 7).

A widely used class of heterogeneous catalysts are zeolites, which are microporous crystalline solids with well-defined structures. They are used as solid-acid catalysts in petrochemical processing. They are also a helpful tool for better understanding the effects of the environment of the catalytically active site, such as the pore wall, solvents, ligands, and the interaction with adsorbates. The NRSC-Catalysis report points out that various molecular-synthesis techniques can be used to activate zeolites for other reactions such as selective oxidation or dehydrogenation (5).

One interesting application is the development of selective oxidation catalysts by incorporating single-site silsesquioxane clusters connected through a polymeric matrix embedded in the channels of a porous inorganic support. Silsesquioxane clusters are small molecular complexes of silica or alumina, which contain reactive-single site atoms with similar reactivity as the inorganic support of a heterogeneous catalyst (5).

The NRSC-Catalysis program is also developing new designs for microfluidics reactor systems, which can be used for producing well-defined nanoparticles that can be used in heterogeneous catalysts (6). The design of catalysts, carriers, and reactors are interrelated, and studying these interrelationships is an important research area of NRSC-Catalysis. For example, researchers at the University of Nijmegen have built nano-sized reactor architectures with the goal of constructing cell-like assemblies from amphiphilic block copolymers. They developed a procedure to encapsulate enzymes at specific locations in these capsule and have used these systems to perform cascade reactions (5).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here